Predictors of early NEDA-3 status after first disease-modifying therapy in a real-world Brazilian multiple sclerosis cohort

Read full text Summarise with VIRAT
Authors: Flávia Timbó Albuquerque, Felipe Toscano Lins de Menezes, Natasha Pryanca de Araújo Bessa, Nilton Amorim de Souza, Denis Bernardi Bichuetti, Enedina Maria Lobato de Oliveira
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: No evidence of disease activity (NEDA-3) is widely recognized as a key therapeutic goal in multiple sclerosis (MS), reflecting complete suppression of both clinical and radiological activity. Despite its importance, there is limited real-world evidence on NEDA-3 attainment following the initiation of first-line disease-modifying therapy (DMT), particularly in middle-income countries. This study evaluated the proportion of people with MS (PwMS) who achieved NEDA-3 after the first year of treatment and identified clinical predictors associated with this outcome. METHODS: We retrospectively analyzed 332 participants with relapsing-remitting MS who initiated their first DMT at a large tertiary neuroimmunology center in São Paulo, Brazil, between 1994 and 2019. NEDA-3 was defined as the simultaneous absence of relapses, confirmed disability progression, and MRI activity after one year. Logistic regression models identified independent predictors of NEDA-3 status. RESULTS: After one year, 29.2% of participants met NEDA-3 criteria. Lower baseline disability (EDSS ≥3: OR = 0.51, 95% CI: 0.28-0.93; p = 0.027), fewer pre-treatment relapses (OR = 0.84, 95% CI: 0.72-0.98; p = 0.031), and use of moderate/high-efficacy DMTs (OR = 2.94, 95% CI: 1.47-5.88; p = 0.002) increased the likelihood of NEDA-3. In the multivariate model, both pre-treatment relapse counts and DMT efficacy remained independent predictors. CONCLUSIONS: In this real-world cohort, about one-third met NEDA-3 criteria after the first treatment year. Early disease control was more likely with moderate/high-efficacy therapy and a lower prior inflammatory burden. This result highlights the importance of timely and effective treatment in optimizing long-term MS outcomes.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Polyomavirus and related diseases Inflammatory Bowel Disease

Publication details

Journal / source
Multiple Sclerosis and Related Disorders
Volume
109
Pages
107153–107153
Publication date
22 March 2026
Language
EN